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Abstract Pre-clinical studies have supported the use of
mesenchymal stem cells (MSC) to treat highly prevalent
neurodegenerative diseases such as Parkinson’s disease
(PD) but preliminary trials have reported controversial
results. In a rat model of PD induced by MPTP neurotoxin,
we first observed a significant bilateral preservation of
dopaminergic neurons in the substantia nigra and preven-
tion of motor deficits typically observed in PD such as
hypokinesia, catalepsy, and bradykinesia, following intra-
cerebral administration of human umbilical cord-derived
MSC (UC-MSC) early after MPTP injury. However,
surprisingly, administration of fibroblasts, mesenchymal
cells without stem cell properties, as a xenotransplantation
control was highly detrimental, causing significant neuro-
degeneration and motor dysfunction independently of
MPTP. This observation prompted us to further investigate
the consequences of transplanting a MSC preparation
contaminated with fibroblasts, a plausible circumstance in
cell therapy since both cell types display similar immuno-
phenotype and can be manipulated in vitro under the same
conditions. Here we show for the first time, using the same
experimental model and protocol, that transplantation of
UC-MSC induced potent neuroprotection in the brain
resulting in clinical benefit. However, co-transplantation
of UC-MSC with fibroblasts reverted therapeutic efficacy
and caused opposite damaging effects, significantly exac-
erbating neurodegeneration and motor deficits in MPTP-
exposed rats. Besides providing a rationale for testing
UC-MSC transplantation in early phases of PD aiming at
delaying disease progression, our pre-clinical study suggests
that fibroblasts may be common cell contaminants affecting
purity of MSC preparations and clinical outcome in stem cell
therapy protocols, which might also explain discrepant
clinical results.
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Introduction
Stem cell-based neuroprotective and neurorestorative pro-
cesses are among the latest therapeutic strategies currently
under investigation for Parkinson’s Disease (PD). Early
clinical studies on allogeneic transplantation of fetal
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mesencephalic cells in the striatum have shown promising
results, including increase in dopamine synthesis and
attenuation of rigidity and bradykinesia in transplanted
patients [1, 2]. However, further randomized, double
blinded and placebo controlled clinical trials have not
found significant motor improvements, and reported ad-
verse effects such as dystonia and dyskinesia [3, 4]. More
recently, scientific discussions regarding new strategies for
cell therapy in PD have resumed in part due to recent
advances in stem cell research and cumulative clinical
experience [5–7], but divergent opinions prevail. Testing of
alternative types of cells for transplantation, quality criteria
for clinical grade cells, dose regimen and infusion routes, in
addition to therapeutic and possible adverse effects are
examples of fundamental questions that still need to be
addressed at a pre-clinical stage to help designing future
clinical trials for PD treatment.
Animal models of PD have been helpful in studying the
neuropathological aspects of the disease and in testing
novel therapeutic approaches, including transplantation of
human adult [8–11] and embryonic stem cells (ESC) [12].
Pre-clinical studies with human neural stem cells and ESC
have been performed in murine and non-human primate
models with the primary aim of reestablishing the dopami-
nergic system, either by direct replacement of nigrostriatal
neurons or by synthesis of dopamine by the exogenous
cells [13–15]. Mouse iPS (induced pluripotent stem) cells
have also been reported capable of generating neurons and
glial cells both in vitro and in vivo, with functional
recovery effects in a murine model of PD [16].
From these encouraging findings, ensuing practical
issues emerge and should be considered from the clinical
viewpoint. The use of pluripotent ESC and iPS cells is
currently challenging due to ethical, technological, and
safety reasons. In addition to the potential development of
teratomas after transplantation of pluripotent cells, in the
case of genetically reprogrammed cells, it remains unclear
whether iPS cells derived from PD patients would generate
dysfunctional neurons due to inherited genetic alterations
associated with the disease [17]. This concern also applies
to the use of endogenous stem and progenitor cells residing
in the patient’s own tissues. Therefore, obtaining genetically
compatible human neural stem cells and/or neuroprogenitors
for allogeneic transplantation is demanding. Other potential
adverse effects of the transplantation of pluripotent cells and
neuroprogenitors under consideration include improper
neurotransmitter balance and development of aberrant neural
connections that may lead to seizures, inhibition or hyper-
activation of pre-existing neural circuitry, with impacts in
cognition and behavior.
In addition to neuronal replacement, neuroprotective
homeostatic adjustments within the cellular niche are also
important to preserve cell function, tissue integrity, and
physiological balance. Such indirect neuroprotective effects
might be achieved through paracrine effects of the
engrafted cells involving production of anti-inflammatory,
angiogenic, and neurotrophic factors, favoring a repairing
microenvironment within the central nervous system [18].
Indeed, post mortem analysis of PD patients subjected to
allogeneic transplantation of fetal mesencephalic cells
revealed that implanted cells eventually succumb to the
degenerating environment in the patient’s brain [19],
indicating the therapeutic relevance of ameliorating the cell
niche in a diseased brain.
Previous studies have shown that the human umbilical
cord (UC) tissue is richer in mesenchymal stem cells
(MSC) than its respective umbilical cord blood (UCB) [20].
In addition, the UCB- and UC-derived MSC express
distinct repertoires of genes, the latter being enriched in
transcripts of genes related to angiogenesis and neuro-
genesis [21]. Furthermore, MSC are poorly immunogenic
lacking constitutive HLA-class II expression and have
immunosuppressive activity [22]. Such molecular trait and
immunomodulatory attributes of UC-MSC might be bene-
ficial in cell therapy protocols for neurovascular and
chronic neurodegenerative diseases, either in auto- or
allotransplants.
Here, in a first experiment, we investigated the thera-
peutic potential of human UC-MSC in a rat model of PD
induced by the neurotoxin 1-methyl, 4-phenyl, 1, 2, 3, 6-
tetrahydropyridine (MPTP). Distinct intracranial routes of
administration were tested for cell engraftment. Preserva-
tion of dopaminergic neurons in the substantia nigra (SN)
and improvements in motor function were considered as
therapeutic end points, while anxiety and absence of visible
tumor mass were specifically examined as potential adverse
effects. Intracranial infusion of fibroblasts was performed as
an additional xenotransplantation control of human cells
without stem cell properties.
Transplantation of UC-MSC was well tolerated and a
significant and specific therapeutic effect was achieved. To
our surprise, while control animals infused with saline
showed no effects, animals injected with fibroblasts
presented exacerbated neurodegeneration and motor defi-
cits. This observation prompted us to investigate if
contamination of MSC preparations with fibroblasts, which
express several markers in common with MSC, could have
a detrimental as opposed to a beneficial therapeutic effect.
In order to address this question, we performed additional
transplant experiments using UC-MSC mixed with fibro-
blasts. Under such experimental conditions, treatment with
human UC-MSC/fibroblasts did not result in therapeutic
benefit and worsen the neurotoxic and behavioral effects of
MPTP. Possible adverse effects due to poor purity of MSC
preparations have not been properly addressed and they
might provide an explanation for discrepant results in pre-
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clinical and clinical studies observed by different research
groups.
Material and Methods
Isolation and Propagation of Human UC-Derived MSCs
The study was approved by the local institutional review
boards. Ten human UC units were collected after obtaining
informed consent from the donors. MSC were isolated and
characterized in vitro as previously described [21]. Briefly,
UCs were filled with 0.1% collagenase (Sigma-Aldrich,
St. Louis) in phosphate-buffered saline (PBS) and incu-
bated at 37°C for 20 min. Each UC was washed with
proliferation medium consisting of DMEM-LG, 10% fetal
bovine serum (FBS), 100 U/mL penicillin and 1%
penicillin/streptomycin. Detached cells were harvested by
gently massaging the UC. Cells were centrifuged at 300 g
for 10 min, resuspended in proliferation medium, and
seeded in 25 cm2 flasks at a density of 5×107 cells/mL.
After 24 h of incubation at 37°C in 5% CO2, non-adherent
cells were removed, and culture medium was replaced
every 3 days. Adherent cells (third passage, at 80–90%
confluence) were subjected to adipogenic, chondrogenic,
and osteogenic differentiation in vitro according to estab-
lished protocols [22], for multipotency testing.
Dermal fibroblasts were obtained from skin biopsies of
healthy adult women after informed consent. Skin samples
were dissected, sliced into 2–3 mm2 pieces with sterile
scalpel and forceps, and transferred to cell culture dishes
(Corning) in DMEM High Glucose medium, supplemented
with 20% of FBS and 1% of Antibiotics (GIBCO,
Invitrogen). Culture dishes were incubated at 37°C and
5% CO2 and left undisturbed for 48 h to prevent tissue
dislodging. The growth medium was changed every 3 days.
Fibroblasts began to outgrowth from skin explants after 7–
8 days of culture. When cells were about 70–80%
confluent, they were dissociated from the dish surface
using a trypsin solution (TryPLE Express; GIBCO, Invitrogen)
and subcultured in DMEM High Glucose medium, with 10%
FBS and 1% of Antibiotics (GIBCO, Invitrogen). Cells were
purified and expanded by serial passaging until their charac-
terization and use in the xenotransplant experiments, as
performed for UC-MSC.
Expression of typical MSC cell-surface markers was
evaluated by flow cytometry. Adherent cells were trypsi-
nized, washed, and incubated with the following anti-
human primary antibodies: CD29-PECy5, CD34-PerCP,
CD31-phycoerythrin (PE), CD45-fluorescein isothiocya-
nate (FITC), CD90-R-PE, CD73-PE, CD13-PE, CD44-PE,
CD117-PE, human leukocyte antigen (HLA)-ABC-FITC,
HLA-DR-R-PE (Becton, Dickinson and Company, Franklin
Lakes, NJ). A total of 10,000 labeled cells were analyzed
using a Guava EasyCyte flow cytometer running Guava
ExpressPlus software (Guava Technologies Hayward, CA).
(Supplemental Figure 1).
Experimental Model of PD
Male adult Wistar rats (200–250 g) were housed under
standard controlled conditions (7:00 AM/7:00 P.M. light/
dark cycle; 20–22°C; 45–55% humidity) with food and
water ad libitum. All efforts were made to minimize animal
suffering following the proposal of International Ethical
Guideline for Biomedical Research (CIOMS/OMS, 1985).
The study was approved by the Ethics Committee for
Animal Research of the Federal University of São Paulo,
Brazil (CEP 2071/07).
Experimental animals (n=10 per group) were subjected
to a toxin-induced model of PD. Damage to the nigrostriatal
dopaminergic system was induced with the neurotoxin
MPTP-HCl (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
hydrochloride - Sigma-Aldrich, St. Louis) dissolved in
saline (0,9% NaCl) at a final concentration of 2 mg/mL.
MPTP was infused via intranasal with a peristaltic pump set
at a flaw rate of 12.5 μL/min, as previously described [23].
A PE-50 catheter was inserted 8 mm deep into the nasal
cavity. The inhalation lasted four minutes per nostril
(0.1 mg/50 μL), with 1 min interval between each
inhalation. Control animals received the same amount of
saline only.
Cell Transplantation Protocol
One week after MPTP or saline treatment, animals were
subjected to intracranial infusion of either vehicle (sham),
human fibroblasts (cellular control), human UC-MSC, or a
mixture of 50% UC-MSC and 50% fibroblasts (n=10, per
experimental group). Animals were anesthetized with
sodium thiopental (75 mg/kg, i.p.) and a concentrated
suspension of cells (105 in 5 μL of DMEM-LG without
FBS) was injected with a high precision 10 μL micro-
syringe (Hamilton Co.) in the right striatum (Bregma
+0.70 mm AP, +3.0 mm ML, −4.5 mm DV) or in the right
ventricle (Bregma −0.80 mm AP, −1.5 mm ML, −3.5 mm
DV) through a stereotaxic brain surgery. Sham animals
received 5 μL of DMEM-LG without FBS only. Motor
deficits and brain histology were evaluated 4 weeks after
initial exposure to MPTP or saline (i.e. 3 weeks after cell
transplantation).
Behavioral Assessment
Different behavioral tests were applied to address the
effects of MPTP administration on motor activity and
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emotionality of experimental animals. Hypokinesia was
determined based on exploratory activities and locomotion
measured by the open field test [24]. Animals were
positioned in the center of a circular arena (100 cm
diameter, 40 cm high) divided in 18 squares, and the
number of squares crossed by the rats was registered for
5 min. Catalepsy and bradykinesia were determined based
on the animal’s ability to correct its posture and time of
immobility in the tail suspension test, respectively [25].
Animals were placed in a head-down position and the
capacity and latency to orient in the head-up position were
video recorded. Anxiety was evaluated by the elevated-plus
maze test. The maze was comprised by two open arms
(29 cm × 5 cm), two closed arms (29 cm × 5 cm × 15 cm),
and a central region (5 cm × 5 cm). Animals were
positioned in the center of the maze and behavior was
observed for 5 min. Anxiety levels were determined by the
percentage of time spent in the open arms relative to the
total time spent in both open and closed arms [26].
Data were analyzed by Two-way ANOVAwith Bonferroni
as post-hoc test. All conclusions were based on at least 5%
level of significance (P≤0.05).
Immunofluorescence
Human cells were detected in rat brains by immunofluores-
cence using antibodies specific to human DNA. Animals
were deeply anesthetized with sodium pentobarbital (75 mg/
kg i.p.) and perfused transcardially with PBS pH 7.4 for
30 min (12 mL/min rate), followed by 4% paraformaldehyde
in PBS for 40 min. Brains were transferred to a 4%
paraformaldehyde solution for 24 h, cryoprotected in a
30% sucrose solution for 3 days, and sectioned at 70 μm on a
cryostat. Tissue sections were blocked with 10% FBS, 5%
bovine serum albumin (BSA), and 0.1% Triton X-100 in
PBS for 1 h at room temperature and incubated at 4°C
overnight with primary antibody (mouse anti-human nuclei
CAT#MAB1281, Chemicon International, California, USA)
at a 1:20 dilution, followed by incubation with secondary
anti-mouse IgG antibody at a 1:100 dilution for 2 h at room
temperature. Tissues were counterstained with 5 μg/mL 4′,6-
Diamidino-2-phenylindol (DAPI) and microscope slides
mounted in Vectashield medium (Vector Laboratories).
Immunofluorescence analysis was performed in a Zeiss
Imager Z1 Apotome microscope with epi-fluorescence, or
using an argon ion laser scan microscope LSM 410 (Zeiss –
Jena, Germany). Images were captured and digitalized with
the Axiovision 4.8 software.
Quantification of Dopaminergic Neurons
Brain sections were cut at a 70 μm thickness using a
vibratome (Leica VT 1000s) and dopaminergic neurons
were detected with antibody against tyrosine hydroxylase
(TH) (ABCAM, cat# ab113). The sampled sections were
chosen according to the systematic random sampling
scheme, with a section sampling fraction (ssf) of 1/5. After
quenching endogenous peroxidases with 3% H2O2 in PBS
for 10 min, sections were incubated for 2 h with 10% BSA/
0,3% Triton X-100, and then incubated with primary
antibody at a 1: 2000 dilution overnight at 4°C, followed
by incubation with biotinylated anti-mouse IgG (Vector) at
1:200 dilution for 2 h at room temperature. Immunostaining
was performed with 90-min incubation in avidin-biotin
peroxidase complex (ABC Vector Lab) and detection in
0.075% DAB (diaminobenzidine, Sigma-Aldrich) with
30% H2O2.
TH+ neurons were estimated by stereology using the
optical-fractionator design [27]. This method includes the
use of an optical dissector at regularly predetermined x, y
axis within the SN of Wistar rat. The SN was delineated
using 1× magnifications according to the delimitations
given by Paxinos (1995) [28]. Step “x” was predetermined
to 200 μm and step “y” to 200 μm. Microscopic (Carl
Zeiss, Imager M1, Germany) images obtained from SN
using 63× objective captured and an unbiased counting
frame was then superimposed using the Stereoinvestigator
8.21 software (MicroBrightField, Colchester, VT, USA).
The counting frame area of the dissector (70 μm×70 μm=
4900 μm2) was focused through 70 μm thickness and the
number of neurons counted with unbiased counting rules.
The height of the dissector was 10 μm for this study. At
each step in the sampled cell, the distance between the top
and bottom surfaces were determined [29], indicating that
shrinkage is homogeneous within each studied section. All
sections after processing and mounting were on average
17 μm (±1.85 s.d.) thick. The fraction of the sampled
section thickness is referred to as the thickness sampling
fraction (tsf) = h (the height of the disector)/t (the mean
thickness of the section).
TH+ neurons were directly counted in the established
fraction of the SN. Coefficient of error (CE) for cell number
estimates was calculated from the formula:
CEðNÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CE2 þ CE2ðtÞ2
q
adopting the one-stage systematic sampling procedure (CE
Scheaffer-Mendenhall-Ott) that has been applied and
validated elsewhere [30].
We also estimated the total volume (Vol) in the SN with
the Cavalieri method:
Volref ¼ t  a x; ystepð Þ  1ssf ΣP
where t is the mean section thickness, ∑P is the sum of
upper right corner points of the counting frames that lie
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within the region of interest, and a is the area associated
with the x,y-step lengths.
Results
Engraftment of Human Cells into the Brains
of Immunocompetent Rats
Prior to the in vivo trial, two intracranial infusion routes
were evaluated with regards to human cell engraftment.
Identical amounts of human UC-MSC were infused either
in the right lateral ventricle or locally in the right striatum.
The injection in the ventricular system was attempted to
facilitate cell distribution to the main components of the
basal ganglia, including striatum and SN. However, 1 week
post- intracerebroventricular (i.c.v.) administration of UC-
MSC, only a few isolated cells could be detected in rat
brains, mainly in the ipsilateral striatum relative to the
injection site. Similar distribution pattern was observed in
rats previously exposed to MPTP. One week after i.c.v.
administration, a limited amount UC-MSC could be
observed in the vicinity of the right ventricle. When human
fibroblasts were injected via i.c.v., engrafted cells were
rarely detected in brains of control and MPTP-treated rats
(Fig. 1a–c).
Alternatively, when directly injected into the right
striatum, a greater amount of grafted UC-MSC could be
detected in rat brains even 3 weeks after cell administration.
UC- MSC could be detected not only in the vicinity of the
injection site, where they were present at a high density, but
also in other brain regions such as the medial septal
nucleus, peripheral zone of the striatum, and in the SN
(Fig. 1d–i). Noteworthy, at the striatum, UC-MSC were
detected in both ipsilateral and contralateral sites. Interest-
ingly, the existence of neurodegeneration due to previous
exposure to MPTP did not change this distribution pattern.
Similar results were obtained in animals that inhaled either
saline or MPTP 1 week prior to cell injection. As observed
with the i.c.v. route, when injected in the striatum,
biodistribution of human fibroblasts was similar to that of
UC-MSC, even though fewer engrafted cells could be
detected (Fig. 2).
Intrastriatal Infusion of UC-MSC Preserves
Dopaminergic Neurons
Since human cell grafts were more efficiently formed
through intrastriatal cell infusion, this administration route
was chosen to further examine potential therapeutic effects
of UC-MSC in rats subjected to the experimental model of
PD induced by MPTP. One week post-MPTP or -saline
(control) inhalation, animals were infused with vehicle
(sham), human UC-MSC, human UC-MSC plus human
fibroblasts (50% each), or human fibroblasts (as a cellular
control). Immunohistochemical analysis of dopaminergic
(TH+) neurons revealed a marked bilateral neurodegenera-
tion in the SN, 4 weeks after MPTP exposure (Fig. 3).
Tyrosine hydroxylase is a rate-limiting enzyme in dopamine
synthesis that localizes in the cytosol and synaptic termini.
Qualitative analysis of control-sham rat brains showed a
cluster of TH+ neurons in the SN with many TH+ termini
in the background (Fig. 3a–b). In addition to neuronal loss,
the remaining TH+ neurons in the SN of sham rats exposed
to MPTP displayed a different cytoarchitecture character-
ized by citoplasmatic retraction and scarce TH+ synaptic
termini (Fig. 3c–d).
However, animals exposed to MPTP and later treated
with UC-MSC displayed preserved dopaminergic neu-
rons in the SN. Both cytoarchitecture and immunohisto-
chemical staining pattern were similar to those found in
the SN of control animals. Interestingly, such preserva-
tion of dopaminergic neurons was also observed in the
contralateral SN relative to the cell infusion site.
Conversely, similar neuropreservation was neither found
in fibroblast-treated nor in UC-MSC plus fibroblast-
treated animals that had been previously exposed to MPTP
(MPTP-fibroblasts, and MPTP-UC-MSC/fibroblasts,
respectively).
Further quantitative analysis by stereology confirmed
neurodegeneration induced by MPTP and neuropreserva-
tion in rats subsequently treated with UC-MSC. As shown
in Fig. 4, rats exposed to MPTP (MPTP-sham) contained
nearly half TH+ neurons in the SN after 4 weeks, compared
with control animals (control-sham). Under the same time
frame, rats that received an infusion of UC-MSC 1 week
after MPTP exposure had significantly higher amounts of
TH+ neurons in the SN than MPTP-sham, MPTP-UC-
MSC/fibroblasts, and MPTP-fibroblast rats. Such amount
was equivalent to that found in control-sham animals and is
in agreement with the amount detected in normal rats
[31]. Histological analysis did not detect intracranial tumors
in animals infused either with UC-MSC or fibroblasts
(Supplemental Figure 2).
Fig. 1 Engraftment of human UC-MSC and fibroblasts in rat brains.
Cells were injected either in the right cerebral ventricle (a–c) or
directly into the right striatum (d–o) of control and MPTP-injured rats.
Human cells could be detected by immunofluorescence 1 week post-i.
c.v. injection and 3 weeks post-intrastriatal injection. The white arrows
indicate examples of cells that reacted positively with DAPI (blue
fluorescence) and antibody specific to human DNA (red fluorescence).
UC-MSC in MPTP-injured rats (a, b, d–f), UC-MSC in control rats
(g–i), fibroblasts in MPTP-injured rats (c, j–l), fibroblasts in control
rats (m–o). Bar scale 50 μm
b
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Intrastriatal Infusion of Human Fibroblasts Induces
Neurodegeneration in the SN
The stereological analysis of SN also revealed a significant
reduction in the amount of TH+ neurons in animals that
received an infusion of human fibroblasts. As indicated
in Supplemental Table 1, fibroblast-treated animals had
SN of similar volume but with significantly reduced
quantity of TH+ neurons than animals of all other
experimental groups. Such reduction was observed both
in control and MPTP-exposed animals, attaining similar
amounts of TH+ neurons 3 weeks from the fibroblast
injection (5.1×103 and 4.7×103 cells, respectively). Such
amounts correspond to about 34–37% the amount of TH+
neurons present in the SN of control-sham animals.
Surprisingly, the reduction in TH+ neurons induced by
intrastriatal human fibroblast injection was significantly
higher than the reduction caused by MPTP neurotoxicity
alone, suggesting a potent neurodegenerative effect.
Noteworthy, significant degeneration of TH+ neurons
after injection of UC-MSC alone or UC-MSC plus
fibroblasts were also found in control animals.
Prevention of Motor Deficits in MPTP-Injured Rats
Due to UC-MSC Treatment is Reverted
by Fibroblast Contamination
MPTP neurotoxicity in rats caused motor deficits that were
evident 4 weeks after the MPTP inhalation. Compared with
control-sham animals, MPTP-sham animals presented
symptoms of hypokinesia, indicated by significant lower
locomotor activity measured by the open field test.
Symptoms of catalepsy and bradykinesia were also detected
4 weeks after MPTP inhalation, indicated respectively by a
significant lower capability of posture recovery and
increased immobility time (Fig. 5a–c). Fibroblast transplan-
tation in control animals also caused significant hypokine-
sia and catalepsy. Hypokinesia, but not catalepsy and
bradykinesia, was also verified in control animals trans-
planted with UC-MSC.
Conversely, MPTP-exposed animals that were treated
with UC-MSC displayed indexes of locomotion, reflex, and
time of immobility that were comparable to those observed
in control-sham animals. No significant signs of hypoki-
nesia, catalepsia, and bradykinesia were observed in the
Bregma –5.3
Bregma + 0.70 Bregma -0.80
SN
Bregma –5.3
a b
Fig. 2 Scheme illustrating intracerebral distribution of engrafted human
cells. a Intrastriatal administration, b i.c.v. administration. The arrows
indicate the site of cell injection. Colored circles indicate major
locations of engrafted human cells within rat brains. Green: Control -
UC-MSC, red: MPTP - UC-MSC, orange: Control – Fibroblast, blue:
MPTP - Fibroblast. Cpu = caudatus putamen; SN = substantia nigra
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Fig. 3 Population of dopaminergic neurons in the SN of rats indicated
by immunohistochemistry with anti-tyrosine hydroxylase. Rats
inhaled either saline (control) or MPTP and 1 week later were
subjected to an intrastriatal injection of vehicle (sham), human UC-
MSC and/or human fibroblasts. Immunohistochemical analyzes were
performed 4 weeks post injury with MPTP (i.e. 3 weeks post
intrastriatal injections). TH+ neurons at both ipsilateral (a, c, e, g, i,
k, m, o) and contralateral (b, d, f, h, i, l, n, p) sites relative to
intrastriatal injection are shown. Control-Sham (a, b), MPTP-Sham (c,
d), Control-UC-MSC (e, f), MPTP - UC-MSC (g, h), Control-UC-
MSC/fibroblast (i, j), MPTP-UC-MSC/fibroblast (k, l), Control-
fibroblast (m, n), MPTP-fibroblast (o, p). Bar scale 50 μm
Control – Sham
MPTP – UC-MSC
Control – UC-MSC
Control – UC-MSC / Fibroblast
Control – Fibroblast
MPTP – Sham
MPTP – Fibroblast 
MPTP – UC-MSC / Fibroblast
**
***
* **
No
.
 
TH
+
n
e
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Fig. 4 Amount of TH+ neurons
in the SN of control and MPTP-
injured rats. One week post
MPTP inhalation, rats were
subjected to an intrastriatal
injection of vehicle (sham),
human UC-MSC and/or human
fibroblasts. Control animals
inhaled saline. Data represent
mean values quantified 4 weeks
post injury with MPTP. Statistical
significance: * P≤0.05,
** P≤0.01, *** P≤0.005
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UC-MSC-treated animals. More importantly, such thera-
peutic effects of UC-MSC could not be observed when they
were mixed with fibroblasts. The behavioral tests detected
significant differences in the motor activity of MPTP-UC-
MSC animals compared with MPTP-sham, MPTP-UC-
MSC/fibroblasts and MPTP-fibroblasts animals. No signif-
icant differences were noted in the anxiety levels of animals
due to MPTP exposure or human cell transplantation
(Fig. 5d).
Discussion
Mesenchymal stem cells from human cord are emerging as
suitable candidates for use in cell therapy protocols due to
their multipotency and immunomodulatory properties.
From the practical viewpoint, UC-MSC can be isolated at
high yields and in vitro expanded by simple procedures that
are feasible to adapt in a hospital routine. The existing
infrastructure for cryopreservation of umbilical cord blood
may also facilitate banking of the entire umbilical cord unit
for future clinical applications [21]. However, here we
show that the lack of proper quality control and poor purity
of MSC preparations may induce adverse as opposed to
benefitial effects and affect overall clinical outcome. In this
work, the therapeutic properties of UC-MSC were further
evaluated in an experimental model of PD, revealing novel
findings with clinical implications.
Our first observation was that intracranial infusion of
UC-MSC in the lateral ventricle did not facilitate cell
engraftment in components of the basal ganglia. Since
asymmetrical lateral ventricular enlargement is associated
with motor asymmetry and progression in PD [32],
injection of cells in the ventricular system would be a
convenient approach allowing cell contact with different
brain regions affected in PD including striatum, pallidum,
substantia nigra, and subthalamic nucleus, as well as the
cerebral cortex. However, UC-MSC were rarely seen in rat
brains 1 week after i.c.v. administration. Only a few
isolated cells were detected, mostly in the striatum.
In fact, cell engraftment and biodistribution were
improved by direct injection of cells in the right striatum.
Through this administration route, cells could even be
detected in the contralateral striatum and other brain
structures distant from the injection site, including the SN,
indicative of cell migration. Migration of MSC within the
brain has also been reported in hemiparkinsonian rats
injured with 6-hydroxy-dopamine [8]. Neurotrophic
factor-secreting MSC isolated from rat [10] and human
[11] bone marrow that were transplanted into rat striatum
have been shown to migrate from the striatum and corpus
callosum toward sites of injury. While our results confirmed
the ability of MSC to migrate within the brain and reach the
SN, no indications of preferential cell homing to brain
injured tissue were observed. The biodistribution of UC-
MSC after either i.c.v. or intrastriatal injections were similar
in control rats and in rats with neurodegeneration caused by
Fig. 5 Motor activity of rats subjected to the MPTP model of PD.
Rats inhaled either saline (control) or MPTP and 1 week later were
subjected to an intrastriatal injection of vehicle (sham), human UC-
MSC and/or human fibroblasts. Behavioral tests were performed
4 weeks post injury with MPTP. a Hypokinesia based on locomotor
activity determined by the open field test. b Catalepsy determined by
the percentage of animals capable of recovering position on the tail
suspension test, c Bradykinesia based on time of immobility in the tail
suspension test, d Anxiety evaluated by the elevated-plus maze test.
Statistical significance: * P≤0.05, *** P≤0.005
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previous exposure to MPTP. Since UC-MSC were inocu-
lated 1 week after MPTP inhalation, active cell homing
through chemoattraction might possibly involve factors
secreted in earlier stages of neurodegeneration. Previous
reports of active MSC homing also indicate requirement of
supplementary neurotrophic brain factors [10, 11]. In any
event, these results suggest that intracranial transplantation
of MSC close to injured sites may be more advantageous in
clinical trials than systemic administration.
The second observation was that, even though present in
small quantities in the rat brain, UC-MSC were capable of
protecting the dopaminergic neurons in the SN against the
neurotoxic effects of MPTP. This observation is supported
by the similar amounts of TH+ neurons found in the SN of
control rats (i.e. not exposed to MPTP) and rats exposed to
MPTP but subsequently treated with UC-MSC. More
importantly, this neuroprotection effect occurred bilaterally
and was specifically caused by the UC-MSC grafts since
the same phenomenon was not observed in MPTP-exposed
rats that were later infused with either vehicle or human
fibroblasts, where a significant degeneration of TH+
neurons occurred in SN. A recent study with modified
human bone marrow MSC transplanted in the striatum of
hemiparkinsonian rats injured with 6-hydroxy-dopamine
[11] reported that most MSC were destroyed by the rat
immune system 1 week post-injection, although a small
amount of cells could still be detected 50 days post-
injection. A similar situation was found in the present study,
suggesting that even small amounts of remaining human
MSC in the host’s brain may exert a potent neuroprotector
effect. The fact that neuropreservation in SN occurred
bilaterally further reinforces this point.
Furthermore, the neuroprotector effect caused by UC-
MSC transplantation also prevented motor deficits resulting
from the MPTP neurotoxicity. In fact, besides inducing a
bilateral neurodegeneration in the SN, another advantage of
the MPTP model of PD is that it allows the use of different
behavioral tests to address motor function. In the present
study, rats exposed to MPTP and subsequently treated with
UC-MSC did not show motor dysfunctions typically
observed in PD patients such as hypokinesia, catalepsy,
and bradykinesia, as opposed to MPTP-exposed rats that
were infused either with vehicle or fibroblasts. Such
specific functional effects of UC-MSC were detected as
early as 3 weeks after cell transplantation, emphasizing a
potent therapeutic effect. Intracranial transplantation of UC-
MSC did not generate tumors and did not cause effects
related to anxiety or depression in rats.
The third observation was provided by the additional
cellular control of xenografted cells included in the present
study which revealed that transplantation of human cells
without stem cell properties may be deleterious. Intrastriatal
transplantation of human fibroblasts in rats induced a
significant degeneration of TH+ neurons in the SN that
resulted in motor deficits. While engraftment of human UC-
MSC in the brain of immunocompetent rats was expected
due to the immunossupressor activity of MSC, human
fibroblast grafts had not been anticipated. This could be
partially explained by the fact that the experiments involved
a single intracranial cell injection and that the brain is an
immunoprivileged organ protected by the hematoencefalic
barrier. Nonetheless, given that fewer fibroblasts were
detected in rat brains than UC-MSC, the significant
reduction in TH+ neurons in the SN of fibroblast-treated
rats is indicative of a potent neurotoxic effect.
More importantly, presence of fibroblasts as a cell
contaminant in the UC-MSC preparation abolished the above
mentioned therapeutic effects of stem cell transplantation and
further enhanced degeneration of dopaminergic neurons.
Since fibroblasts do not share the same immunomodulatory
properties of MSC, the observed neurodegeneration could be
partly explained by xenograft rejection. In a clinical scenario,
although such rejection would not occur in autotransplanta-
tion, abolishment of therapeutic effects by fibroblasts could
considerably affect clinical outcome. However, when using
human umbilical cord as a source of MSC, allotransplants are
likely to be more frequent than autotransplants. In this
scenario, the presence of contaminant allogeneic fibroblasts
may induce inflammation and a local immune response.
Indeed, in a preliminary clinical trial with PD patients
subjected to allotransplantation of mesencephalic tissue,
Olanow et al. [4] reported inflammation and activated
microglia around brain grafts, indicating immune reaction.
Such immune rejection of brain allografts were reported to
be involved in the degeneration of dopaminergic neurons
and occurrence of diskinesias observed in some PD patients
[7]. Since inflammation and immune reaction within the
brain are known to contribute to neurodegeneration in PD,
as well as in other prevalent neurodegenerative diseases
[33], contamination of MSC preparations with fibroblasts
should be carefully controlled in allogeneic transplantation.
Recent advances in stem cell research include the
identification of a variety of stem cell types coming from
alternative biological sources or technological procedures,
which pose the challenge of understanding the advantages
and disadvantages of each particular cell type to pursue
prospective therapeutic applications. The therapeutic effects
observed in rats treated with UC-MSC are comparable to
those reported with transplantation of neurons that had been
differentiated from embryonic stem cells and iPS cells in
experimental models of PD [15, 16, 34]. However, instead
of direct reconstitution of dopaminergic neurons alone, the
mechanisms of UC-MSC-mediated neuroprotection may
also involve paracrine effects towards an improved micro-
environment in the central nervous system, favoring
restoration in detriment of degeneration [35, 36]. The
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discrepancy in the amount of engrafted UC-MSC in the SN
and the respective extensive preservation of TH+ neurons
quantified by stereology, in addition to the bilateral neuro-
protector effect observed, all support this hypothesis.
Intriguingly, partial recovery of TH+ neurons has been
reported in rats lesioned with 6-hydroxy-dopamine, albeit
only 12 weeks post MSC transplant, a time when engrafted
cells could no longer be detect in rat brains [9], suggesting
mobilization of endogenous neuroprogenitors. However,
the intrinsic mechanism involved is currently unclear and
should be further addressed.
Conclusion
This pre-clinical study of cell therapy in PD reveals potent
and specific effects of intrastriatal transplantation of human
UC-MSC regarding bilateral preservation of dopaminergic
neurons in the SN and prevention of motor deficits. Such
therapeutic effects, however, were reversed and an enhanced
neurodegeneration was observed when the UC-MSC prepa-
ration was also comprised by fibroblasts, a mesenchymal cell
type without stem cell properties.
The neurotoxic effect observed due to transplantation
of human fibroblasts suggests that purity of cell
preparations must be carefully considered in clinical
trials, in particular those involving allotransplantation,
to avoid possible severe adverse effects. Cell population
heterogeneity may also explain different results observed
in previous pre-clinical and clinical trials. Another
distinctive aspect of the present study is that cell
transplantation was performed 1 week after MPTP
exposure, when dopamine deficiency and neurodegenera-
tion are still progressing and motor activity is not fully
affected [23]. Since this experimental situation is more
associated with the initial phase of PD, our findings
provide a rationale for clinical trials of UC-MSC trans-
plantation with the aim of delaying disease progression
and ensuing intensification of motor deficits, through
neuroprotective homeostatic adjustments in the brain.
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